高危型人乳头瘤病毒及雌、孕激素受体在宫颈癌及癌前病变中的表达及临床意义

Clinical significance and expression of HR-HPV,ER,PR in cervical cancers

目的:探讨高危型人乳头瘤病毒及甾体类激素受体ER、PR在宫颈癌及癌前病变中的表达及临床病理意义。方法:采用原位杂交及免疫组织化学染色方法检测HPV、ER、PR在不同程度的宫颈病变组织中的表达情况。结果:HPV16/18在正常宫颈组织表达率为0,随着病变严重程度的增加,HPV16/18的表达率逐渐升高,至高度上皮内瘤变组(CINII、III级)达高峰。HPV16/18在各组间的表达差异具有显著统计学意义(P<0.01)。HPV31/33主要在低度上皮内瘤变组中表达。ER、PR的表达率及表达强度随着病变程度的增加逐渐降低,各组间的差异具有显著的统计学意义(P<0.01)。结论:HR-HPV感染是诱发宫颈癌的首要启动因素,ER、PR在HPV感染引起的宫颈癌早期起促进作用,但PR也可能起抑制作用。

Objective：To explore the expression of HR-HPV and ER,PR in cervical cancer tissues with different degree of severity and its clinicopathologic significance.Methods：Immunihistochemistry and in situ hybridisation were used to detect the expression of HR-HPV and ER,PR in normal cervical tissues,cervical intraepithelial neoplasm（CIN） and cervical cancers.Results：The positive rate of HPV16/18 was 0 in the normal cervical tissue,its positive rate and staining intensity increased with the severity of the disease arrived at peak at high intraepithelial neoplasia（CIN II,III）.There was significant difference（P0.01）between different groups.HPV31/33 was detected dominantly in group CIN I.The staining intensity and positive rate of ER,PR were significant different（P0.01）between different groups.Conclusion：HR-HPV may play an principal start role in the pathogenesis of cervical cancer.ER,PR serve as promoting effect in early cervical cancer caused by HPV,but PR may has an inhibitory effect.